Key statistics
As of last trade, IGC Pharma Inc (IGS1:STU) traded at 0.270, 25.00% above the 52 week low of 0.216 set on Jan 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.296 |
---|---|
High | 0.306 |
Low | 0.270 |
Bid | 0.276 |
Offer | 0.338 |
Previous close | 0.278 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.64m |
Free float | 69.65m |
P/E (TTM) | -- |
Market cap | 26.62m USD |
EPS (TTM) | -0.2104 USD |
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Press releases
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
- IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
- IGC Announces Results of its 2024 Annual Stockholders Meeting
- IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
- IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
- IGC Pharma Reports First Quarter Fiscal 2025 Results
- IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
- Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
- IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
More ▼